Skip to main content
Erschienen in: Clinical and Experimental Nephrology 6/2018

11.06.2018 | Original Article

Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b–4 stages chronic кidney disease patients: a randomized pilot study

verfasst von: Lyudmila Milovanova, Victor Fomin, Sergey Moiseev, Marina Taranova, Yury Milovanov, Lidia Lysenko (Kozlovskaya), Vasiliy Kozlov, Elena Kozevnikova, Svetlana Milovanova, Marina Lebedeva, Vladimir Reshetnikov

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

A low protein diet (LPD) with essential amino acid ketoanalogue supplementation (KA) may contribute in improving of chronic kidney disease (CKD), while the exact mechanisms of KA’s effect are not established yet. We have conducted a prospective, randomized, controlled comparative study of LPD + KA and LPD alone in relation to serum Klotho, FGF-23 levels in CKD patients.

Methods

79 non-diabetic CKD 3b–4 stage patients, compliant with LPD diet (0.6 g/kg of body weight/day), had been selected. The patients were randomized into two groups. The first group (42 patients) received LPD + КA. The second group (37 patients) continued the LРD alone. In addition to routine tests, serum Klotho, FGF-23 levels, as well as bioimpedance analysis, sphygmography (stiffness (augmentation) indices (AI), central (aortal) blood pressure) with a «SphygmaCor» device; echocardiography (valvular calcification score (VCS) and LVMMI), were performed.

Results

There were body mass indices’ decrease (p = 0.046), including muscle body mass in men (p = 0.027) and woman (p = 0.044) in the LPD group to the end of study (14th month). In addition, lower FGF-23 (p = 0.029), and higher sKlotho (p = 0.037) were detected in the LPD + KA group compared to the LPD one. The increase in AI (p = 0.034), VCS (p = 0.048), and LVMMI (p = 0.023) was detected more often in the LPD group at the end of study.

Conclusion

LPD + KA provides support for nutrition status and contributes to more efficient correction of FGF-23 and Klotho abnormalities that may result in cardiovascular calcification and cardiac remodeling decreasing in CKD. At the same time, a prolonged LPD alone may lead to malnutrition.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.CrossRef Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.CrossRef
2.
Zurück zum Zitat Eckardt K-U, Kasiske BL, et al. KDIGO clinical practice guideline for the diagnosis, evolution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Elsevier. 2009;76:S1–130.CrossRef Eckardt K-U, Kasiske BL, et al. KDIGO clinical practice guideline for the diagnosis, evolution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Elsevier. 2009;76:S1–130.CrossRef
3.
Zurück zum Zitat Piccoli GB, Capizzi I, Vigotti FN, Leone F, D’Alessandro C, Giuffrida D, et al. Low protein diets in patients with chronic kidney disease: a bridge between mainstream and complementary-alternative medicines? BMC Nephrol. 2016;17:1–13.CrossRef Piccoli GB, Capizzi I, Vigotti FN, Leone F, D’Alessandro C, Giuffrida D, et al. Low protein diets in patients with chronic kidney disease: a bridge between mainstream and complementary-alternative medicines? BMC Nephrol. 2016;17:1–13.CrossRef
8.
Zurück zum Zitat Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–92.CrossRef Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–92.CrossRef
17.
Zurück zum Zitat Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370–8.CrossRef Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370–8.CrossRef
20.
Zurück zum Zitat Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51.CrossRef Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51.CrossRef
21.
Zurück zum Zitat Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al. Suppression of aging in mice by the Hormone Klotho. Science. 2005;309:1829–33.CrossRef Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al. Suppression of aging in mice by the Hormone Klotho. Science. 2005;309:1829–33.CrossRef
22.
Zurück zum Zitat Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med Massachusetts Med Soc. 2004;351:1296–305.CrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med Massachusetts Med Soc. 2004;351:1296–305.CrossRef
24.
Zurück zum Zitat Hu M-C, Shi M, Cho HJ, Zhang J, Pavlenco A, Liu S, et al. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int. 2013;84:468–81.CrossRef Hu M-C, Shi M, Cho HJ, Zhang J, Pavlenco A, Liu S, et al. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int. 2013;84:468–81.CrossRef
27.
Zurück zum Zitat Ermolenko VM, Volgina GV, Dobronravov VA, et al. National recommendations on mineral and bone disorders in chronic kidney disease. Russian Dialysis Society (May 2010).Nephrologia I Dialis. 2011;13(1):33–51. Ermolenko VM, Volgina GV, Dobronravov VA, et al. National recommendations on mineral and bone disorders in chronic kidney disease. Russian Dialysis Society (May 2010).Nephrologia I Dialis. 2011;13(1):33–51.
30.
Zurück zum Zitat Milovanova LY, Mukhin NA, Kozlovskaya LV, Milovanov YS, Kiyakbaev GG, Rogova IV, et al. Decreased serum levels of klotho protein in chronic kidney disease patients: clinical importance. Vestn Ross Akad Meditsinskikh Nauk. 2016;71:288–96. https://doi.org/10.15690/vramn581.CrossRef Milovanova LY, Mukhin NA, Kozlovskaya LV, Milovanov YS, Kiyakbaev GG, Rogova IV, et al. Decreased serum levels of klotho protein in chronic kidney disease patients: clinical importance. Vestn Ross Akad Meditsinskikh Nauk. 2016;71:288–96. https://​doi.​org/​10.​15690/​vramn581.CrossRef
34.
Zurück zum Zitat Steitz SA, Speer MY, Curinga G, Yang H-Y, Haynes P, Aebersold R, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147–54.CrossRef Steitz SA, Speer MY, Curinga G, Yang H-Y, Haynes P, Aebersold R, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147–54.CrossRef
Metadaten
Titel
Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b–4 stages chronic кidney disease patients: a randomized pilot study
verfasst von
Lyudmila Milovanova
Victor Fomin
Sergey Moiseev
Marina Taranova
Yury Milovanov
Lidia Lysenko (Kozlovskaya)
Vasiliy Kozlov
Elena Kozevnikova
Svetlana Milovanova
Marina Lebedeva
Vladimir Reshetnikov
Publikationsdatum
11.06.2018
Verlag
Springer Singapore
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 6/2018
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-018-1591-1

Weitere Artikel der Ausgabe 6/2018

Clinical and Experimental Nephrology 6/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.